Similarly, AKT inhibitor was used in lung cancer with KEAP1 mutation through interaction of cellular antioxidant pathway (Fan et al., 2023) and could assist to kill tumor cell (Dai et al., 2013). Here, AKT1 is linked to lung carcinoma.